Stocks
Funds
Screener
Sectors
Watchlists
TWST

TWST - Twist Bioscience Corp Stock Price, Fair Value and News

$43.31+0.29 (+0.67%)
Delayed

34/100

TWST

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

34/100

TWST

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

TWST Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TWST Price Action

Last 7 days

-7.7%

Last 30 days

-12.7%

Last 90 days

40.0%

Trailing 12 Months

10.7%

TWST RSI Chart

TWST Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TWST Valuation

Market Cap

2.7B

Price/Earnings (Trailing)

-34.67

Price/Sales (Trailing)

6.78

EV/EBITDA

-49.11

Price/Free Cashflow

-30.62

TWST Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

TWST Fundamentals

TWST Revenue

Revenue (TTM)

391.6M

Rev. Growth (Yr)

16.89%

Rev. Growth (Qtr)

4.74%

TWST Earnings

Earnings (TTM)

-76.6M

Earnings Growth (Yr)

3.44%

Earnings Growth (Qtr)

-12.41%

TWST Profitability

Operating Margin

51.62%

EBT Margin

-19.33%

Return on Equity

-16.79%

Return on Assets

-12%

Free Cashflow Yield

-3.27%

TWST Investor Care

Shares Dilution (1Y)

2.78%

Diluted EPS (TTM)

-1.27

TWST Alerts

  • 8 major insider sales recently.
  • Losses in recent quarter

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025347.7M362.3M376.6M391.6M
2024277.5M295.2M313.0M330.2M
2023227.8M235.5M245.1M262.4M
2022163.1M184.2M203.6M215.8M
2021113.0M126.8M132.3M146.2M
202065.8M73.4M90.1M101.1M
201940.0M47.1M54.4M60.1M
201818.1M21.8M25.4M32.6M
20170010.8M14.4M
TWST
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
 CEO
 WEBSITEtwistbioscience.com
 SECTORHealthcare
 INDUSTRYDiagnostics & Research
 EMPLOYEES989

Twist Bioscience Corp Frequently Asked Questions


TWST is the stock ticker symbol of Twist Bioscience Corp. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of Twist Bioscience Corp is 2.66 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Mar 13 2026, TWST's PE ratio (Price to Earnings) is -34.67 and Price to Sales (PS) ratio is 6.78. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TWST PE ratio will change depending on the future growth rate expectations of investors.